RENEURON GRP PLC LS-01
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in… Read more
RENEURON GRP PLC LS-01 (RQE1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, RENEURON GRP PLC LS-01 (RQE1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
RENEURON GRP PLC LS-01 - Net Assets Trend (None–None)
This chart illustrates how RENEURON GRP PLC LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RENEURON GRP PLC LS-01 (None–None)
The table below shows the annual net assets of RENEURON GRP PLC LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to RENEURON GRP PLC LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
RENEURON GRP PLC LS-01 Competitors by Market Cap
The table below lists competitors of RENEURON GRP PLC LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Exemplar REITail Ltd
JSE:EXP
|
$1.63 Million |
|
ARCUS DEVELOPMENT
MU:AJR
|
$1.63 Million |
|
Diagnamed Holdings Corp.
PINK:DGNMF
|
$1.63 Million |
|
Damodar Industries Limited
NSE:DAMODARIND
|
$1.63 Million |
|
Guardforce AI Co. Limited Warrant
NASDAQ:GFAIW
|
$1.63 Million |
|
ASTRAZENECA
HM:ZEG
|
$1.63 Million |
|
RYDER SYSTEM - Dusseldorf Stock Exchang
DU:RYD
|
$1.63 Million |
|
ORACLE
BE:ORC
|
$1.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RENEURON GRP PLC LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares RENEURON GRP PLC LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently RENEURON GRP PLC LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares RENEURON GRP PLC LS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RENEURON GRP PLC LS-01 (RQE1) | €- | N/A | N/A | $1.63 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |